Skip to main content
Premium Trial:

Request an Annual Quote

NuGen and Caliper to Co-develop Automated Library Construction for Next-Gen Sequencing

Premium

This story was originally published Jan. 27.

NuGen Technologies and Caliper Life Sciences said last week that they will co-develop automated methods for sample prep on Caliper's Sciclone NGS Workstation.

The partners aim to enable automatic processing from a wide range of sample types, such as nucleic acids extracted from sorted cells, fine needle aspirates, formalin-fixed paraffin embedded tissue, and other limited or degraded clinical samples.

The companies will first co-develop a method for RNA-seq library construction from as little as 500 picograms of total RNA, which they expect to be available in March. The method will make use of NuGen's Ovation RNA-seq system and Encore NGS Multiplex System I and will run on Caliper's Sciclone NGS Workstation.

NuGen's CEO Elizabeth Hutt said in a statement that the company's RNA-seq system is the first kit without any requirement for poly-A selection or ribosomal RNA depletion, which "results in a more complete data set and a more comprehensive understanding of the transcriptome, including non-coding RNA."

Aside from RNA-seq library construction, the companies plan to develop automated library construction methods for other applications, including digital gene expression, whole genome, and exome sequencing.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more